The FDA recently approved a pretzel-shaped implant that helps some bladder cancer patients keep their bladder. Dr. Chris ...

Discover how the ALYREF biomarker predicts bladder cancer aggressiveness and boosts immunotherapy response. Find out more ...

The IMvigor010 trial showed that Signatera-guided treatment with Tecentriq improved disease-free survival and overall ...

TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...

People with type 1 diabetes (previously called juvenile diabetes) are 4.29 times more likely to develop bladder cancer, ...

Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease.

The bladder cancer treatment landscape is rapidly evolving, particularly for patients who don’t respond to bacillus ...

A slow drug-release system has proven highly effective in treating certain bladder cancer patients whose tumors were previously unresponsive to therapy. A new targeted drug delivery system known as TA ...

Bladder cancer ranks among the ten most common types of cancer worldwide. The main treatment is bladder removal surgery, and despite advances in systemic therapies, recurrence is frequent in the most ...

People with type 1 diabetes (previously called juvenile diabetes) are 4.29 times more likely to develop bladder cancer, ...

The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.

Based on patterns of recurrence-free survival (RFS) over time in some studies, the researchers determined that 5-year RFS may be a suitable surrogate for measuring cure. In considering outcomes for ...